1-4 of 4
Jim Leisten
Close
Sort by
Journal Articles

CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma

Soraya Carrancio, Lynda Groocock, Preethi Janardhanan, Diana Jankeel, Ryan Galasso, Carla Guarinos, Rama K. Narla, Matthew Groza, Jim Leisten, Daniel W. Pierce, Mark Rolfe, Antonia Lopez-Girona
Journal: Blood
Blood (2021) 138 (Supplement 1): 1200.
https://doi.org/10.1182/blood-2021-148068
Published: 2021
Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce
Journal: Blood
Blood (2019) 134 (Supplement_1): 1815.
https://doi.org/10.1182/blood-2019-124345
Published: 2019
Journal Articles

The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Emily Rychak, Ph.D., Derek Mendy, B.S., Karen Miller, B.S., Jim Leisten, B.S., Rama Krishna Narla, Ph.D., Heather K Raymon, Ph.D., Rajesh Chopra, M.D., Ph.D., Antonia Lopez-Girona, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3160.
https://doi.org/10.1182/blood.V122.21.3160.3160
Published: 2013
Journal Articles

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Soraya Carrancio, PhD, Jennifer A Markovics, PhD, Piu Wong, PhD, Jim Leisten, Matthew C Groza, Heather K Raymon, Carla Heise, PhD, Rajesh Chopra, MD, PhD, Tom O Daniel, MD, PhD, Victoria Sung, PhD
Journal: Blood
Blood (2012) 120 (21): 372.
https://doi.org/10.1182/blood.V120.21.372.372
Published: 2012